A review of exenatide as adjunctive therapy in patients with type 2 diabetes

@inproceedings{Robles2009ARO,
  title={A review of exenatide as adjunctive therapy in patients with type 2 diabetes},
  author={Gisela I Robles and Devada Singh-Franco},
  booktitle={Drug design, development and therapy},
  year={2009}
}
BACKGROUND Incretin glucagon-like peptide-1 (GLP-1) is a hormone released from cells in the gastrointestinal tract (GI), leading to glucose-dependent insulin release from the pancreas. It also suppresses postprandial hyperglycemia, glucagon secretion and slows gastric emptying. Exenatide (EXE), a functional analog of human GLP-1, was approved by the US FDA in April 2005. OBJECTIVE This article reviews current primary literature on the clinical efficacy and safety of EXE in the treatment of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Diabetes Mellitus

  • CL Cook, JT Johnson, WE. Wade
  • Principles and Practice.1st ed
  • 2008
Highly Influential
12 Excerpts

The effect of adding exenatide to a thiazolidinediones in suboptimally controlled type 2 diabetes

  • B Zinman, BJ Hoogwerf, SD Garcia
  • Ann Intern Med
  • 2007
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…